医学
抗抑郁药
舍曲林
精神科
重性抑郁障碍
系统回顾
心理干预
观察研究
人口
荟萃分析
不利影响
梅德林
内科学
认知
焦虑
环境卫生
政治学
法学
作者
Eleni Niarchou,LH Roberts,Bernard Naughton
标识
DOI:10.1177/02698811231224171
摘要
Background: Medication adherence is a prerequisite to achieving beneficial treatment outcomes. In major depressive disorder, many patients fail to complete medication regimens, raising concern for poor treatment outcomes. It is usual to experience adverse drug reactions (ADRs) while taking antidepressants, and relative discomfort is reported by patients. Aims: The present review focuses on the presence of antidepressant-related side effects and the subsequent relationship with medication non-adherence. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. Following the preliminary research, the research question and eligibility criteria were created based on the PICO framework. All articles retrieved from the selected databases were exported to Covidence, a Systematic Review managing software tool. Two reviewers assessed the papers to identify the risk of bias using the Joanna Briggs Institute critical appraisal tool for cross-sectional studies. Seven studies with a low–moderate risk of bias fulfilled the eligibility criteria and were conducted from 2013 to 2020 in Europe, Africa and Asia. Results: The results demonstrated high levels of suboptimal adherence ranging from 46% to 83% amongst the studied population. A variety of side effects were reported by a significant number of participants predominantly with moderate severity. A correlation between the presence of ADRs and suboptimal rates of adherence to antidepressants was found. Somnolence and headaches among other unspecified ADRs were found to increase the dropout rates for selective serotonin reuptake inhibitors. Conclusions: The present study elucidates the need for effective interventions to facilitate antidepressant adherence and enhance doctor–patient communication, benefiting both the individuals and the healthcare system and leading to better clinical outcomes and reduction of relapse-related costs.
科研通智能强力驱动
Strongly Powered by AbleSci AI